Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $...








